US FDA approves Lilly’s breast cancer drug combination

• In a late-stage study of 159 patients, the combination extended median time before cancer worsened to 11.1 months versus 5.5 months for Inluriyo alone
• About half of patients with ER-positive, HER2-negative metastatic breast cancer develop ESR1 mutations during or after hormone-blocking therapy
• The combination carries significant risks including severe diarrhea, low white blood cell counts, lung inflammation, liver problems, blood clots, and embryo-fetal toxicity

Summary

Key Approval: The US FDA has approved Eli Lilly's Inluriyo-Verzenio combination therapy for treating adults with advanced estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer carrying an ESR1 mutation that has spread throughout the body.

Target Patient Population: The combination targets patients whose cancer has progressed after at least one hormone treatment. Approximately 50% of ER+/HER2- metastatic breast cancer patients develop ESR1 mutations during or after hormone-blocking therapy. HR+/HER2- represents the most common breast cancer subtype, with breast cancer being the second leading cause of cancer death in women.

Clinical Data: The approval was based on a late-stage study of 159 patients showing significant improvement. Patients receiving the combination therapy experienced a median progression-free survival of 11.1 months compared to 5.5 months for those taking Inluriyo alone—effectively doubling the time before cancer worsened.

Treatment Details: Inluriyo, a daily pill that blocks and degrades estrogen receptors, was previously approved by the FDA in September of last year. Verzenio, a twice-daily pill, works by slowing cancer cell division. The combination is now immediately available in the United States.

Safety Profile: The treatment carries notable risks including severe diarrhea, low white blood cell counts, lung inflammation, liver problems, blood clots, and embryo-fetal toxicity warnings for pregnant patients.

Market Context: Eli Lilly recently became the first pharmaceutical company to reach a $1 trillion market valuation, joining an exclusive club previously dominated by tech giants, driven partly by its success in the weight-loss drug market.